Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SEPNthis companySepterna Inc	$49.50	-25.35×	3.23×	26.85×	-24.05×	-147.7%	100.0%	-175.8%	-106.4%	-12.8%	-15.8%	8.9%	0.06×	2.05×	0×	4.73×	0.0%	3	6.86	2	C
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
GPCRStructure Therapeutics Inc.	$21.32	-28.98×	2.72×	0×	-23.85×	-35.6%	0.0%	0.0%	0.0%	-9.3%	-18.9%	-5.5%	0×	5.69×	0×	24.81×	0.0%	1	9.92	2	C+
KLRAKailera Therapeutics, Inc.	$13.88	-20.63×	-8.6×	0×	-18.46×	-89.9%	0.0%	0.0%	0.0%	41.8%	-24.5%	-4.0%	-0.03×	0.95×	0×	12.01×	0.0%	—	—	2	C+
MAZEMaze Therapeutics, Inc.	$34.25	-13.58×	5.02×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-36.9%	-37.7%	-6.3%	0.07×	1.29×	0×	15.5×	0.0%	3	11.54	2	C
MBXMBX Biosciences, Inc. Common Stock	$53.81	-13.25×	3.12×	0×	-12.42×	-96.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-7.1%	0×	0.86×	0×	24.62×	0.0%	1	58.99	2	C
Peer median	—	-13.58×	2.72×	0×	-12.54×	-87.4%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-6.3%	0×	0.95×	0×	15.5×	0.0%	1	10.73	2	—